Showing 2871-2880 of 5804 results for "".
- FDA Approves Juvéderm Volbella XC for Use in Lips and Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-juvderm-volbella-xc-for-use-in-lips-and-perioral-rhytids/2458546/Allergan plc, has received FDA approval to market Juvéderm Volbella XC for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. In clinical trials, Juvéderm Volbella XC was found to effecti
- Galderma Introduces New Mirvaso Pump Dispenser to Treat Persistent Facial Redness of Rosaceahttps://practicaldermatology.com/news/galderma-introduces-new-mirvaso-pump-dispenser-to-treat-persistent-facial-redness-of-rosacea/2458549/Galderma Laboratories, L.P. launched a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33% for the treatment of the persistent facial redness associated with rosacea. The Mirvaso Gel Pump is now available by prescription to patients in pharmacies nationwide. The improved
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee
- Cynosure Receives FDA Clearance to Market PicoSure Energy Delivery System for Tattoos and Pigmented Lesionshttps://practicaldermatology.com/news/cynosure-receives-fda-clearance-to-market-picosure-energy-delivery-system-for-tattoos-and-pigmented-lesions/2458554/The FDA granted clearance to Cynosure to market a new Laser Delivery System for PicoSure. Together with the FDA cleared 532nm and 755nm wavelengths, Cynosure's new 1064nm Laser Delivery System improves the multi-wavelength laser technology for removing the full color spectrum of tattoo inks i
- Feet Get Skin Cancer Too, ACFAS Warnshttps://practicaldermatology.com/news/feet-get-skin-cancer-too-acfas-warns/2458565/Skin cancer of the foot is prevalent and can be fatal if not caught early, the American College of Foot and Ankle Surgeons (ACFAS) warns. While all types of skin cancer, including squamous cell and basal cell carcinoma, can be found
- Alphaeon Launches PROVOQUE™ Facial Serumhttps://practicaldermatology.com/news/alphaeon-launches-provoque-facial-serum/2458567/Alphaeon Corporation has launched PROVOQUE™ Facial Serum to help address the visible signs of skin aging. PROVOQUE Facial Serum is a stem cell-conditioned media containing growth factors secreted by stem cells.
- FDA Approves New Combo Drug Plus Device Treatment for AKshttps://practicaldermatology.com/news/fda-approves-new-combo-drug-plus-device-treatment-for-aks/2458568/The FDA approved Biofrontera AG’s combination topical prescription drug Ameluz (BF-200 ALA) and medical device BF-RhodoLED for photodynamic therapy (PDT) treatment of mild-to-moderate actinic keratosis (AK) on the face and scalp. The approval covers lesion-directed as well as field-directed
- Dermira's Novel Facial Acne Treatment Passes Muster in Phase 2b Studyhttps://practicaldermatology.com/news/dermiras-drm01-performs-well-in-facial-acne-study/2458571/Dermira’s novel topical sebum inhibitor -- DRMO1 -- may put the brakes on facial acne, according to topline results from a Phase 2b dose-ranging study that is paving the way toward a Phase 3 Clinical Program. DRM01 is a novel, small molecul
- Sienna Biopharmaceuticals Completes $34 Million Series A Financinghttps://practicaldermatology.com/news/sienna-biopharmaceuticals-completes-34-million-series-a-financing/2458586/Sienna Biopharmaceuticals, Inc., a development stage company focused on aesthetics and medical dermatology, completed a $34 million Series A financing led by ARCH Venture Partners. Additional investors included Altitude Life Science Ventures, Partner Fund Management, and Venvest Capital, as well
- SCCA Doctors Address the Future of Immunotherapy for Melanomahttps://practicaldermatology.com/news/scca-doctors-address-the-future-of-immunotherapy-for-melanoma/2458600/Immunotherapy is the hottest topic in cancer care today, and metastatic melanoma is among the first type to benefit from this fourth cancer therapy. Two Seattle Cancer Care Alliance (SCC